DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights.
Epigenomics
; 7(7): 1137-53, 2015 Oct.
Article
in En
| MEDLINE
| ID: mdl-26067621
ABSTRACT
AIM:
To define the DNA methylation landscape of neuroblastoma and its clinicopathological impact. MATERIALS &METHODS:
Microarray DNA methylation data were analyzed and associated with functional/regulatory genome annotation data, transcriptional profiles and clinicobiological parameters.RESULTS:
DNA methylation changes in neuroblastoma affect not only promoters but also intragenic and intergenic regions at cytosine-phosphate-guanine (CpG) and non-CpG sites, and target functional chromatin domains of development and cancer-related genes such as CCND1. Tumors with diverse clinical risk showed differences affecting CpG and, remarkably, non-CpG sites. Non-CpG methylation observed essentially in clinically favorable cases was associated with the differentiation status of neuroblastoma and expression of key genes such as ALK.CONCLUSION:
This epigenetic fingerprint of neuroblastoma provides new insights into the pathogenesis and clinical behavior of this pediatric tumor.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Gene Expression Regulation, Neoplastic
/
Receptor Protein-Tyrosine Kinases
/
Cyclin D1
/
Epigenesis, Genetic
/
Neuroblastoma
Type of study:
Diagnostic_studies
/
Prognostic_studies
Limits:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Language:
En
Journal:
Epigenomics
Year:
2015
Document type:
Article
Affiliation country:
Spain